Nature系列综述:利用复制应激治疗癌症的现状与展望

2015-05-13 佚名 生物谷

近日,丹麦科学家Claus Storgaard S?rensen在国际学术期刊nature reviews drug discovery发表了一篇综述文章,对利用癌细胞DNA复制应激进行癌症治疗的相关研究进展进行了总结讨论和展望。   癌细胞的DNA复制一般会伴随着复制叉的拖延和崩溃,以及应答DNA损伤和未成熟有丝分裂的信号通路激活,这些过程统称为"复制应激"。目前有许多研究对复

近日,丹麦科学家Claus Storgaard S?rensen在国际学术期刊nature reviews drug discovery发表了一篇综述文章,对利用癌细胞DNA复制应激进行癌症治疗的相关研究进展进行了总结讨论和展望。
 
癌细胞的DNA复制一般会伴随着复制叉的拖延和崩溃,以及应答DNA损伤和未成熟有丝分裂的信号通路激活,这些过程统称为"复制应激"。目前有许多研究对复制应激过程进行了大量探讨,并在这方面取得了显著进展,增加了人们对于调节复制应激过程的分子机制的理解,同时,也为通过增强复制应激开发癌症治疗手段提供了大量机会。除了拖延癌细胞周期进展,癌症治疗还可以进一步促进癌细胞通过周期检验点,增加复制应激,最终诱导细胞增殖的毁灭性失败,从而达到杀伤癌细胞治疗癌症的目的。
 
在这篇综述文章中,作者对目前的相关研究进展进行了总结。首先对DNA复制应激以及肿瘤细胞内的复制应激过程进行了系统性介绍,随后作者对可增强复制应激的药物以及其他可增强复制应激的方式进行了总结,提出将药物进行联合使用或与传统的化疗方法结合可进一步促进DNA复制应激,并且在一些病例中已经证明药物联合使用具有协同作用。但利用DNA复制应激进行癌症治疗也存在一些风险,作者在文章中针对应用该策略治疗癌症的风险以及如何保护正常细胞进行了总结和讨论。
 
最后,作者对未来利用DNA复制应激治疗癌症如何选取治疗靶点进行了探讨和展望。
 
综上所述,该文章对利用DNA复制应激进行癌症治疗的相关研究进展进行了总结,作者提出了许多新的问题和想法,并对未来如何进行DNA复制应激机制研究以及选取治疗靶点进行了探讨和展望,对于开发新的癌症治疗策略具有重要指导意义。

原始出处:

Matthias Dobbelstein & Claus Storgaard Sørensen.Exploiting replicative stress to treat cancer.Nature Reviews Drug Discovery, May 8, 2015.doi:10.1038/nrd4553

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1880647, encodeId=fb19188064e0b, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Dec 21 00:07:00 CST 2015, time=2015-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24422, encodeId=e89d24422df, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b64e106775, createdName=cement123, createdTime=Thu May 21 13:35:00 CST 2015, time=2015-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445099, encodeId=5ce11445099c5, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Fri May 15 00:07:00 CST 2015, time=2015-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23337, encodeId=5e952333ed8, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed May 13 20:21:00 CST 2015, time=2015-05-13, status=1, ipAttribution=)]
    2015-12-21 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1880647, encodeId=fb19188064e0b, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Dec 21 00:07:00 CST 2015, time=2015-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24422, encodeId=e89d24422df, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b64e106775, createdName=cement123, createdTime=Thu May 21 13:35:00 CST 2015, time=2015-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445099, encodeId=5ce11445099c5, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Fri May 15 00:07:00 CST 2015, time=2015-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23337, encodeId=5e952333ed8, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed May 13 20:21:00 CST 2015, time=2015-05-13, status=1, ipAttribution=)]
    2015-05-21 cement123

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1880647, encodeId=fb19188064e0b, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Dec 21 00:07:00 CST 2015, time=2015-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24422, encodeId=e89d24422df, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b64e106775, createdName=cement123, createdTime=Thu May 21 13:35:00 CST 2015, time=2015-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445099, encodeId=5ce11445099c5, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Fri May 15 00:07:00 CST 2015, time=2015-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23337, encodeId=5e952333ed8, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed May 13 20:21:00 CST 2015, time=2015-05-13, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1880647, encodeId=fb19188064e0b, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Dec 21 00:07:00 CST 2015, time=2015-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24422, encodeId=e89d24422df, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b64e106775, createdName=cement123, createdTime=Thu May 21 13:35:00 CST 2015, time=2015-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445099, encodeId=5ce11445099c5, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Fri May 15 00:07:00 CST 2015, time=2015-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23337, encodeId=5e952333ed8, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed May 13 20:21:00 CST 2015, time=2015-05-13, status=1, ipAttribution=)]
    2015-05-13 huaxipanxing

    看看

    0

相关资讯

PNAS:DNA复制停顿的地方可能发生癌变

人类细胞每次分裂,必须先复制出自身 46 条染色体,作为给新细胞的一套“指令手册”。通常情况下,整个程序会自动运转到结束而不出故障。但偶尔也会有意外,信息没复制上又没有适当核对,造成了缺口或断裂,细胞就不得不小心地把它们重新连接起来。染色体中某些区域被称为“脆弱位点”,更容易断裂,这些位点也是人类癌症滋生的地方。 日前,来自杜克大学的一个研究小组绘制出了一份综合的酵母菌基因脆弱位点图,显示了这些脆

LavaAmp:可放进口袋里的实时PCR仪

掌上 PCR就像当年苹果公司的可放进信封的 MacBook Air 笔记本给人带来的震惊一样, LavaAmp 也一样神奇:一台小到可以别在裤腰带上、能够随时随地复制 DNA 序列的链式反应仪。LavaAmp 的样机是用金属薄片做成的,一端有个小小的圆筒形突起部分,上面绕着两根细导线。你可以用5号电池给它供电,或者直接把它连接到笔记本电脑上的 USB 接口也行。 LavaAmp